Amgen Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Amgen Inc. (AMGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.00% for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-24.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2014-02-24
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2013 was 0.00%.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2012 was -0.20%, a 109.09% decline from fiscal 2011.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2011 was 2.20%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2013-12-31 | 0.00% 10-K · filed 2014-02-24 |
| 2012-12-31 | -0.20% 10-K · filed 2014-02-24 |
| 2011-12-31 | 2.20% 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |